Skip Ribbon Commands
Skip to main content


  1. Schmid P, Cortes J, Dent R. Pembrolizumab in Early Triple-Negative Breast Cancer. Reply. New Engl J Med. 2022 May; 386(18):1771-1772 (JIF: 91.245)
  2. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New Engl J Med. 2022 Mar; 386(10):942-950 (JIF: 91.245)
  3. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New Engl J Med. 2022 Feb; 386(6):556-567 (JIF: 91.245)
  4. Tonorezos ES, Cohn RJ, Glaser AW, Lewin J, Poon E, Wakefield CE, Oeffinger KC. Long-term care for people treated for cancer during childhood and adolescence. Lancet. 2022 Apr; 399(10334):1561-1572 (JIF: 79.321)
  5. Lim HY, Heo J, Kim TY, Tai WMD, Kang YK, Lau G, Kudo M, Tak WY, Watras M, Ali SK, Negro A, Abou-Alfa GS, Kelley RK. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348). J Clin Oncol. 2022 Feb; 40(6_Suppl):436 (JIF: 44.544)
  6. Toh HC, Galle PR, Zhi AX, Nicholas A, Gaillard V, Decreux M, Cheng AL, Finn RS. IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study. J Clin Oncol. 2022 Feb; 40(6_Suppl):470 (JIF: 44.544)
  7. Ling ASM, Hankasson AK, Ong EHW, Lau ASY, Low KP, Wong TR, Tan N, Tan JSH, Tuan JKL, Tan TWK, Wang MLC, Tay KJ, Yeong JPS, Lee LS, Kanesvaran R, Tan MCS, Davicioni E, Khor LY, Chua MLK. Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829 patient cohort. J Clin Oncol. 2022 Feb; 40(6_Suppl):273 (JIF: 44.544)
  8. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022 Feb; 40(6):611-625 (JIF: 44.544)
  9. Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2022 Jan; 40(3):242-251 (JIF:44.544)
  10. Moreno V, Lin JJ. Tan DSW, Lassen UN, Leyvraz S, Liu Y, Patel J, Rosen L, Solomon B, Rudolph M, Norenberg R, Schulz A, Fellous, Brega N, Shen L, Kummar S, Drilon A. 61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib Ann Oncol. 2022 Apr; 33(Suppl 2):S60 (JIF: 32.976)

* These are the top 10 publications in DMO for 2022.